Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study

By sjmartinez • May 18, 2025

Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H, Angel B, Li Q, Chen X, Paller AS. Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study. J Am Acad Dermatol. 2025 May 14:S0190-9622(25)02124-3. doi: 10.1016/j.jaad.2025.05.1385. Epub ahead of print. PMID: 40378883.

Tags: atopic dermatitis, children, Dermatology, eczema, efficacy, JAK inhibitor, Janus kinase, pediatric, phase 3, Publications, randomized, ruxolitinib cream, safety, topical

Laboratory monitoring in patients with moderate to severe plaque psoriasis

Fenkel JM, Osborne JA, Armstrong AW, Strober B, Stein Gold L, Cameron M, Lebwohl M. Laboratory monitoring in patients with moderate to severe plaque psoriasis.[...]

Alopecia areata is associated with adverse pregnancy outcomes in a retrospective cohort study using TriNetX

Podolsky AS, Singal A, Goh C, Lipner SR. Alopecia areata is associated with adverse pregnancy outcomes in a retrospective cohort study using TriNetX. J Am[...]

Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, Bernstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L,[...]